Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 19, 2026

A New U.S. Facility Could Break China’s Grip on Critical Materials

View original at finance.yahoo.com
A New U.S…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Washington may have only two months of critical rare-earth inventories available for defense manufacturing if supply disruptions deepen

    60% confidence
  • In the last 10 to 15 years, the majority of the upstream and midstream supply chain for rare earth has been controlled by China

    60% confidence
  • Rare earths are essential components in almost all modern products, either directly or in their production

    60% confidence
  • If China said we're not going to give you rare earths, that means no F-35s, no missiles

    60% confidence
  • Suppliers to U.S. aerospace and semiconductor companies have started turning away customers due to tightening rare earth material supplies

    60% confidence
  • In the last 10 to 15 years, China has controlled the majority of upstream and midstream rare earth supply chain

    60% confidence
  • Suppliers to U.S. aerospace and semiconductor companies have started turning away some customers as supplies of niche rare earth materials tighten

    60% confidence
  • If China stopped supplying rare earths, the U.S. would be unable to produce F-35s or missiles

    60% confidence
  • Almost everything you can point to either has rare earths in it to make it work or was produced by something that had rare earths in it to be able to produce that article

    60% confidence
  • Washington may have only two months of critical rare-earth inventories available for defense manufacturing if supply disruptions deepen

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com